2010
DOI: 10.1002/jps.22160
|View full text |Cite
|
Sign up to set email alerts
|

Inhalable Liposomes of Low Molecular Weight Heparin for the Treatment of Venous Thromboembolism

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
33
0
1

Year Published

2011
2011
2023
2023

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 40 publications
(35 citation statements)
references
References 36 publications
1
33
0
1
Order By: Relevance
“…[5][6][7][8][9] Considerable efforts are being made for the development of several administration routes for liposomes, such as inhalational, transdermal, and ocular in addition to injection. [10][11][12][13][14] In contrast, analytical technology for liposome formulations may not be sufficiently mature to assure efficacy and safe performance as well as to direct the optimization of formulations or improvements in manufacturing processes. Drug release characteristics are considered to be one of the important properties to assure the performance of liposome formulations.…”
mentioning
confidence: 99%
“…[5][6][7][8][9] Considerable efforts are being made for the development of several administration routes for liposomes, such as inhalational, transdermal, and ocular in addition to injection. [10][11][12][13][14] In contrast, analytical technology for liposome formulations may not be sufficiently mature to assure efficacy and safe performance as well as to direct the optimization of formulations or improvements in manufacturing processes. Drug release characteristics are considered to be one of the important properties to assure the performance of liposome formulations.…”
mentioning
confidence: 99%
“…Therefore, LMWHs have received widespread acceptance as the anticoagulant of choice not only for short-term treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) (Bai & Ahsan, 2010) but also for prolonged duration thromboprophylaxis in certain pathologic conditions, such as cancer (Schulman, 2003;Kher & Samama, 2005;Debourdeau et al, 2008;Walter et al, 2014). Moreover, LMWHs have been used for maintenance of vessel patency during hemodialysis and artery bypass grafting (Patel et al, 2009), prevention of acute bronchoconstrictor responses and airway hyper-responsiveness in asthma (Campo et al, 1999;Ahmed et al, 2000) and regulation of growth factor activity in various vascular disorders and angiogenesis (Reyes-Ortega et al, 2013).…”
Section: Lmwhs: Chemistry and Pharmacological Actionmentioning
confidence: 99%
“…Long lived pegylated and conventional liposomes encapsulating ardeparin were prepared in the nanosize range (104.8 and 113 nm, respectively) by hydration method Bai & Ahsan, 2010). They were successfully tested for their pharmacological efficacy in rodent models of PE and DVT following pulmonary administration.…”
Section: Nano-delivery Platforms For Lmwhsmentioning
confidence: 99%
“…58 Venöz tromboemboli ve sigaraya bağlı akciğer hasarı ve idiyopatik pulmoner fibroziste inhaler heparinle başarılı sonuçlar alınmıştır. [59][60][61] 4) Antiproteazlar: Kistik fibrozis ve alfa-1 antripsin eksikliğinde inhaler olarak uygulanan alfa-1 antripsin ile hastaların akciğer bulgularında azalma gözlenmiştir. 28,56 5) Hiperkalemi: Hiperkalemi tedavisinde nebülize levalbuterol ve albuterol tedavisi K'yi düşürmede etkili bir tedavi yöntemi olarak düşünülmüştür.…”
Section: ) Gen Terapi Vektörleri (Cftr-avv)unclassified